Viking Therapeutics (VKTX) Convertible Debt (2014 - 2018)

Viking Therapeutics (VKTX) has 5 years of Convertible Debt data on file, last reported at $1.5 million in Q1 2018.

• For the quarter ending Q1 2018, Convertible Debt fell 59.6% year-over-year to $1.5 million; the trailing twelve-month figure through Mar 2018 stood at $1.5 million (down 59.6% YoY), and the FY2017 full-year result was $1.5 million, changed 0.0% from the prior year.
• Convertible Debt steadied at $1.5 million in Q1 2018, from $1.5 million in the prior quarter.
• In the past five years, Convertible Debt ranged from a high of $3.7 million in Q1 2017 to a low of $1.3 million in Q4 2014.
• A 5-year average of $1.8 million and a median of $1.5 million in 2016 frame the typical range for Convertible Debt.
• Across the five-year window, Convertible Debt soared 119.57% in 2016 and sank 59.6% in 2018, its largest moves.
• Tracing VKTX's Convertible Debt over 5 years: stood at $1.3 million in 2014, then jumped by 70.2% to $2.2 million in 2015, then tumbled by 30.28% to $1.5 million in 2016, then changed by 0.0% to $1.5 million in 2017, then changed by 0.0% to $1.5 million in 2018.
• Business Quant data shows VKTX's Convertible Debt at $1.5 million in Q1 2018, $1.5 million in Q4 2017, and $1.5 million in Q3 2017.